Nurix Therapeutics (NASDAQ:NRIX) CFO Sells $74,539.47 in Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) CFO Hans van Houte sold 4,769 shares of the firm’s stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $15.63, for a total value of $74,539.47. Following the completion of the sale, the chief financial officer directly owned 42,745 shares in the company, valued at approximately $668,104.35. This trade represents a 10.04% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Houte Hans Van also recently made the following trade(s):
• On Friday, October 30th, Hans van Houte sold 2,834 shares of Nurix Therapeutics stock. The shares were sold at an average price of $26.28, for a total value of $74,477.52.

NASDAQ NRIX opened at $15.30 on Friday. The company’s 50 day moving average is $24.26 and its 200-day moving average is $20.21. The firm has a market cap of $1.67 billion, a P/E ratio of 6.62 and a beta of 1.80. Nurix Therapeutics, Inc. has a 12-month low of $11.67 and a 12-month high of $28.23.

Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) last issued its earnings results on Tuesday, October 13th. The company reported $4.73 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.60) by $5.33. Nurix Therapeutics had a return on equity of 49.34% and a net margin of 42.01%. The business had revenue of $673.06 million during the quarter, compared to analyst estimates of $24.35 million. Equities analysts expect that Nurix Therapeutics, Inc. will post 1.14 EPS for the current year.

Several large investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC lifted its holdings in Nurix Therapeutics by 95.4% in the 3rd quarter. GAMMA Investing LLC now owns 1,270 shares of the company’s stock valued at $30,000 after acquiring an additional 620 shares during the last quarter. Nykredit A S bought a new stake in Nurix Therapeutics during the 2nd quarter worth $32,000. Integrated Wealth Concepts LLC bought a new stake in Nurix Therapeutics during the 2nd quarter valued at $33,000. Fifth Third Bancorp boosted its holdings in Nurix Therapeutics by 613.8% in the 3rd quarter. Fifth Third Bancorp now owns 1,556 shares of the company’s stock worth $37,000 after buying an additional 1,338 shares during the period. Finally, KBC Group NV purchased a new stake in Nurix Therapeutics during the first quarter valued at about $34,000.

Several research analysts have recently weighed in on the stock. Morgan Stanley upped their price target on shares of Nurix Therapeutics from $36.00 to $38.00 and gave the stock an “overweight” rating in a report on Tuesday, July 28th. Mizuho lifted their price objective on Nurix Therapeutics from $30.00 to $34.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. HC Wainwright raised their price target on shares of Nurix Therapeutics from $34.00 to $36.00 and gave the stock a “buy” rating in a research note on Friday, October 16th. Wells Fargo & Company dropped their target price on shares of Nurix Therapeutics from $25.00 to $20.00 and set an “overweight” rating on the stock in a report on Wednesday. Finally, Oppenheimer upped their price objective on Nurix Therapeutics from $28.00 to $32.00 and gave the stock an “outperform” rating in a report on Tuesday, October 13th. Fourteen analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $34.43.

Check Out Our Latest Report on Nurix Therapeutics

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that regulate the activity and abundance of proteins involved in cancer and immune-related diseases. Its research is based on targeted protein modulation, including the use of the ubiquitin-proteasome system and E3 ligases to selectively eliminate or modify disease-causing proteins.

The company’s pipeline includes oral targeted protein degraders and other small-molecule therapies. Its investigational programs include NX-5948, a Bruton’s tyrosine kinase (BTK) degrader being studied in B-cell malignancies and autoimmune diseases, and NX-2127, an orally administered BTK degrader designed to combine BTK degradation with immune-system modulation.
• Five stocks we like better than Nurix Therapeutics
• CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?
• Array and Shoals Are Merging: Who Really Wins the All-Stock Solar Deal?

Receive News & Ratings for Nurix Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Nurix Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.…Read more by Micah Haroldson